Regeneron Pharmaceuticals and Telix Pharmaceuticals Ltd. entered a collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies. The collaboration combines Regeneron’s biologics expertise, including bispecific antibody discovery, with Telix’s radiopharmaceutical development platform, global manufacturing capabilities and supply chain infrastructure. The collaboration will include multiple solid tumor targets from Regeneron’s portfolio of antibodies, generat...